# HIV mRNA vaccine strategies for efficient priming, diversity and durability of immune responses

> **NIH NIH R61** · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2024 · $892,826

## Abstract

SUMMARY
Conventional vaccine strategies have not induced successful protection to diverse HIV strains. mRNA vaccine
platforms enable novel modalities of antigen delivery for innovative vaccine strategies. The use of mRNA
technology for HIV vaccines holds promise to conquer major barriers to induce protective responses via
broadly neutralizing antibodies (bnAbs). However, mRNA vaccines to express HIV antigens capable of
effectively conferring protective immunity have not been fully explored. Germinal center (GC) responses are
paramount for prophylactic vaccines as they provide a highly specialized environment to affinity mature
antibodies to difficult epitopes on HIV. We have demonstrated that efficient priming and longer duration of GC
responses are likely favorable for broader neutralizing responses against HIV (Nature 2022). mRNA vaccines
against SARS-CoV-2 have been shown to induce long-lasting GC responses after 2 doses, but the biology and
effective manipulation of this process remains elusive. Particularly, a big knowledge gap is how mRNA
vaccine-induced GCs differ from protein vaccines. A second knowledge gap is what mechanisms drive long-
lasting GCs? A third knowledge gap is what immunological signals regulate the output of durable immune
memory? HIV envelope (Env) trimer is the sole antigenic target for neutralizing antibodies. Many experimental
HIV vaccines use soluble forms of Env that expose the immunodominant base of the trimer eliciting non-
neutralizing antibodies. mRNA vaccines allow the realization of membrane-bound Env expression, which can
present antigen in a more native form avoiding exposure of the base. Membrane-bound Env trimers can also
be expressed on nanoparticles such as virus-like particles (VLPs) via mRNA delivery resembling higher density
expression on native virions. Given the potential of long-lasting GC responses and the new modes of antigen
delivery by membrane-bound Env or multimeric Env nanoparticles, we seek to investigate: Are HIV mRNA
vaccines capable of inducing long-lasting GC responses? How can HIV mRNA vaccines optimally prime long-
lasting GC responses? What sequential immunization strategies work best with HIV mRNA vaccines to induce
diverse and durable memory responses? Non-human primates (NHPs) are an invaluable model for studying
this biology and immunology, because of their relatedness to humans.

## Key facts

- **NIH application ID:** 10898515
- **Project number:** 1R61AI183471-01
- **Recipient organization:** LA JOLLA INSTITUTE FOR IMMUNOLOGY
- **Principal Investigator:** PARHAM RAMEZANI-RAD
- **Activity code:** R61 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $892,826
- **Award type:** 1
- **Project period:** 2024-04-01 → 2027-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10898515

## Citation

> US National Institutes of Health, RePORTER application 10898515, HIV mRNA vaccine strategies for efficient priming, diversity and durability of immune responses (1R61AI183471-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10898515. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*